ClinicalTrials.gg
Not yet recruitingNCT06896760Updated Mar 26, 2025

A Mass Balance Study of [14C]ABSK011

A Phase 1 interventional study of [14C]ABSK011 in Healthy Subjects, sponsored by Abbisko Therapeutics Co, Ltd. Not yet recruiting at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a single-site, open-label, single-cohort, single-dose study to assess the absorption, metabolism, and excretion profile of [14C] ABSK011 in healthy adult male subjects. The study plans to enroll 6 to 8 healthy male subjects to ensure at least 6 evaluable subjects.

Read the detailed description

Participants will be screened no more than 14 days before the dose (D-14 through D-3) and admitted to the clinical trial unit 2 days before the dose (D-2). Participants will receive a single oral administration of approximately 200 mg/120 µCi [14C]ABSK-011 suspension after a low-fat breakfast on day 1 morning.

Urine and stool samples will be collected from participants before and at specified intervals between 0 and 192 hours after taking the drug and blood samples will be collected at specified time points between 0 and 120 hours before and after taking the drug.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who fully understand the content, procedures and possible adverse reactions before the study, and voluntarily sign the form, and can complete the study in accordance with the requirements in the protocol;
  2. Healthy male participants aged 18 to 45 years (including 18 and 45 years) at screening;
  3. Weight ≥ 50 kg, (BMI) between 19 and 26 (including 19 and 26), BMI = weight (kg)/height (m) \^2;
  4. Participants must have regular defecation in the past three months;
  5. Male participants of must agree to use effective methods during the study and within 6 months after administration of study drug . Male subjects must agree to not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal and complete physical examination, vital signs, digital rectal examination, laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function, stool routine + occult blood, thyroid function, etc.), 12-lead , chest X-ray (anteroposterior position), abdominal B ultrasound (hepatobiliary, pancreas, spleen and kidney);
  2. Tested positive for any one of the following: serum surface antigen (HBsAg), hepatitis B e antigen (HBeAg), virus (HCV) antibody, (HIV) antigen/antibody, treponema pallidum antibody (Syphilis) screening;
  3. The baseline of heart rate , QTcF interval prolongs ≥450ms; family history of long QT syndrome (Note: QTc interval is corrected by Fridericia formula);
  4. Known or persistent mental disorders that may interfere with the subject's participation in the study, as judged by the investigator;
  5. Known history of allergy to any drug or food;
  6. Participants who have participated in drug trials within 3 months before dosing.
  7. Participants who have participated in this study or any other study related to ABSK011, and have previously exposed to ABSK011;
  8. Known history of drug abuse or tested positive in drug abuse screening;
  9. Participants with any other factors that may influence the participation in the study, which may affect the subject's compliance with the protocol, interfere with the interpretation of the study results, or expose the subject to risk, as judged by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    [14C]ABSK011

    Participants will receive a single oral administration of approximately 200 mg/120 µCi \[14C\]ABSK-011 suspension after a low-fat breakfast on day 1 morning.

    Drug: [14C]ABSK011

Interventions

  • The standard meal was taken the night before administration, and the patient was fasted for at least 10 h without drinking water overnight. The next morning, eat a low-fat meal, finish the meal within 30 minutes, and take the test drug with warm water 30 minutes (±5 minutes) after the beginning of the meal. The total volume of warm water and suspension liquid is about 240 mL. Except for meals and administration, no water was allowed 1 hour before and 1 hour after medication. No food is allowed for 4 hours after taking the medication. Throughout the study, participants received meals provided by the center at approximately the same time each day.

06

What researchers measure

Primary outcomes

  1. Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity (urine and feces)

    To assess the routes and rates of elimination of ABSK011 and its metabolites after single oral administration of \[14C\]ABSK011 in healthy adult male subjects

    Time frame: All excreted urine and feces samples at specified time points during 0-192 hours after dosing will be collected.

  2. Percentage of each metabolite in urine and feces relative to the administered dose (% administered dose), or percentage of metabolites in plasma relative to total exposure AUC (% AUC);

    To determine the metabolism and elimination pathways of ABSK011 after single oral administration of \[14C\] ABSK011 in healthy adult male subjects, and identify major metabolites.All excreted urine and feces samples at specified time points during 0-192 hours after dosing will be collected.

    Time frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol

  3. %AUC

    To evaluate the pharmacokinetics of ABSK011 and its major metabolites in the urine of healthy adult male subjects after a single oral administration \[14C\] of ABSK011.

    Time frame: Conduct testing within 1 month after all subjects collect all samples at all time points required by the protocol

Secondary outcomes

  1. Frequency, type and severity of adverse events/serious adverse events; changes in vital signs, 12-lead ECGs, laboratory tests, etc.

    To assess the safety and tolerability of a single oral dose of approximately \[14C\] ABSK011 in healthy adult male subjects

    Time frame: From signing the ICF until 9 days after the first dosing

07

Study locations

1 site
  • Beijing GoBroad Hospital
    Beijing, Beijing 102206, China
    • Quankun Zhuang, Doctor · Contact
    • Quankun Zhuang, Doctor · Principal investigator
    • Xuemei Liu, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Nov 2025, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2025
First posted
Mar 26, 2025
StartEst.
Apr 7, 2025
Primary completionEst.
Nov 7, 2025
CompletionEst.
Apr 7, 2026
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06896760
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Apr 7, 2025 (estimated)
Primary completion
Nov 7, 2025 (estimated)
Completion
Apr 7, 2026 (estimated)
Last update
Mar 26, 2025

Study contacts

Yuan LU, Doctor
Contact
clinical@abbisko.cn
13700000000
Quankun Zhuang, Doctor
principal investigator · Beijing GoBroad Hospital
Xuemei Liu, Doctor
principal investigator · Beijing GoBroad Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Irpagratinib

Start the discussion